Tiragolumab Plus Atezolizumab Will Not Be Pursued in Further Cervical Cancer Management
January 12th 2024Ritu Salani, MD, MBA, discussed the results from the phase 2 SKYSCRAPER-4 trial, which determined tiragolumab plus atezolizumab should not be used to treat PD-L1–positive recurrent cervical cancer.
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy
A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Building Efficiency and Scaling With a Remote Genetic Counseling Program
Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.
FDA Issues CRL for Zolbetuximab in Advanced CLDN18.2+ Gastric Cancer
January 9th 2024The FDA cannot approve the application for zolbetuximab in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma due to unresolved issues following a pre-license inspection of a third-party manufacturing site.
Bevacizumab/Chemo Before WBRT May Better Control Breast Cancer Brain Metastases
January 9th 2024Data from the phase 2 A-PLUS trial indicate that bevacizumab plus chemotherapy prior to whole brain radiotherapy may be an efficacious systemic strategy for intractable brain and extracranial metastases stemming from breast cancer.
Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer
January 7th 2024Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.
More Support Needed to Mitigate Psychosocial Impacts of Multiple Myeloma
January 5th 2024A population of patients with multiple myeloma describes experiencing challenges including confusion regarding the complexities of their diagnoses and managing chronic treatment-related adverse effects in a qualitative study.